$RGEN
REPLIGEN CORP Stock $rgen

$rgen Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024018809 Filed on February 22, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$151.3M	$155.7M	$638.8M
YoY Change	-17.14%	-16.61%	-20.31%
Cost Of Revenue	$75.83M	$88.14M	$353.9M
YoY Change	-7.35%	-2.83%	2.34%
Gross Profit	$75.51M	$67.61M	$284.8M
YoY Change	-25.1%	-29.62%	-37.49%
Gross Profit Margin	49.89%	43.41%	44.59%
Selling, General & Admin	$60.99M	$57.51M	$218.1M
YoY Change	8.58%	8.03%	1.06%
% of Gross Profit	80.76%	85.07%	76.57%
Research & Development	$11.07M	$10.29M	$42.72M
YoY Change	-8.89%	-7.45%	-2.76%
% of Gross Profit	14.66%	15.21%	15.0%
Depreciation & Amortization	$16.79M	$17.18M	$37.00M
YoY Change	10.09%	19.51%	54.81%
% of Gross Profit	22.24%	25.42%	12.99%
Operating Expenses	$72.06M	$68.49M	$260.8M
YoY Change	5.47%	6.44%	0.41%
Operating Profit	$3.454M	-$887.0K	$54.58M
YoY Change	-88.95%	-102.8%	-75.71%
Interest Expense	$3.619M	-$1.817M	$1.951M
YoY Change	1240.37%	-148.51%	67.9%
% of Operating Profit	104.78%		3.57%
Other Income/Expense, Net	-$3.536M	$6.623M	$9.556M
YoY Change	-173.12%	1543.42%	-272.8%
Pretax Income	$2.114M	-$8.757M	$64.13M
YoY Change	-94.14%	-116.53%	-70.73%
Income Tax	$20.00K	$16.73M	$22.56M
% Of Pretax Income	0.95%		35.17%
Net Earnings	$2.094M	-$25.49M	$41.58M
YoY Change	-92.74%	-152.31%	-77.64%
Net Earnings / Revenue	1.38%	-16.37%	6.51%
Basic Earnings Per Share	$0.04		$0.75
Diluted Earnings Per Share	$0.04	-$0.46	$0.74
COMMON SHARES
Basic Shares Outstanding	55.77M	55.83M	55.72K
Diluted Shares Outstanding	56.53K		56.38K

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$780.6M	$751.3M	$751.3M
YoY Change	26.31%	20.45%	20.45%
Cash & Equivalents	$780.6M	$751.3M	$751.3M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$38.60M	$13.32M	$23.01M
YoY Change	70.86%	29.62%	19.11%
Inventory	$198.0M	$202.3M	$202.3M
Prepaid Expenses
Receivables	$115.8M	$124.2M	$124.2M
Other Receivables	$0.00	$0.00	$10.23M
Total Short-Term Assets	$1.133B	$1.111B	$1.111B
YoY Change	11.21%	11.31%	11.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$340.3M	$207.4M	$323.0M
YoY Change	76.61%	8.79%	2.3%
Goodwill	$986.0M	$987.1M
YoY Change	15.14%	15.38%
Intangibles	$388.1M	$400.5M
YoY Change	11.99%	13.24%
Long-Term Investments
YoY Change
Other Assets	$1.822M	$1.277M	$2.807M
YoY Change	53.37%	56.69%	69.61%
Total Long-Term Assets	$1.716B	$1.713B	$1.713B
YoY Change	12.95%	12.24%	12.24%
TOTAL ASSETS
Total Short-Term Assets	$1.133B	$1.111B	$1.111B
Total Long-Term Assets	$1.716B	$1.713B	$1.713B
Total Assets	$2.849B	$2.824B	$2.824B
YoY Change	12.25%	11.87%	11.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.73M	$19.56M	$19.56M
YoY Change	-29.05%	-29.0%	-29.0%
Accrued Expenses	$49.35M	$50.53M	$39.06M
YoY Change	-14.99%	-28.95%	-30.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$69.48M	$69.45M	$69.45M
YoY Change	-75.63%	-75.6%	-75.6%
Total Short-Term Liabilities	$178.3M	$158.2M	$158.2M
YoY Change	-56.01%	-60.87%	-60.87%
LONG-TERM LIABILITIES
Long-Term Debt	$513.9M	$510.1M	$510.1M
YoY Change
Other Long-Term Liabilities	$148.2M	$3.789M	$144.4M
YoY Change	3804.03%	-0.66%	-22.66%
Total Long-Term Liabilities	$662.1M	$695.0M	$654.6M
YoY Change	244.1%	231.35%	250.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$178.3M	$158.2M	$158.2M
Total Long-Term Liabilities	$662.1M	$695.0M	$654.6M
Total Liabilities	$878.7M	$853.2M	$853.2M
YoY Change	47.0%	38.97%	38.97%
SHAREHOLDERS EQUITY
Retained Earnings	$440.9M	$438.8M
YoY Change	3.48%	10.47%
Common Stock	$1.572B	$1.570B
YoY Change	1.74%	1.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.971B	$1.971B	$1.971B
YoY Change
Total Liabilities & Shareholders Equity	$2.849B	$2.824B	$2.824B
YoY Change	12.25%	11.87%	11.87%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$2.094M	-$25.49M	$41.58M
YoY Change	-92.74%	-152.31%	-77.64%
Depreciation, Depletion And Amortization	$16.79M	$17.18M	$37.00M
YoY Change	10.09%	19.51%	54.81%
Cash From Operating Activities	$44.71M	$29.02M	$113.9M
YoY Change	300.82%	-53.11%	-33.8%
INVESTING ACTIVITIES
Capital Expenditures	$8.373M	$11.09M	$36.22M
YoY Change	-1.6%	-48.16%	-57.3%
Acquisitions			$186.6M
YoY Change
Other Investing Activities	$11.00K	-$158.8M	-$32.00K
YoY Change		58.91%	-70.91%
Cash From Investing Activities	-$8.362M	-$169.9M	-$123.3M
YoY Change	-11.35%	40.04%	-47.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$14.39M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-8.974M	268.2M	249.0M
YoY Change	-6.16%	-97968.98%	-1966.69%
NET CHANGE
Cash From Operating Activities	44.71M	29.02M	113.9M
Cash From Investing Activities	-8.362M	-169.9M	-123.3M
Cash From Financing Activities	-8.974M	268.2M	249.0M
Net Change In Cash	27.37M	127.3M	227.9M
YoY Change	-499.65%	-313.24%	-383.57%
FREE CASH FLOW
Cash From Operating Activities	$44.71M	$29.02M	$113.9M
Capital Expenditures	$8.373M	$11.09M	$36.22M
Free Cash Flow	$36.34M	$17.93M	$77.70M
YoY Change	1273.72%	-55.72%	-10.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000730272
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-14656
CY2023	dei	Entity Registrant Name EntityRegistrantName	REPLIGEN CORP
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-2729386
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	41 Seyon Street, Bldg. 1, Suite 100
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Waltham
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02453
CY2023	dei	City Area Code CityAreaCode	781
CY2023	dei	Local Phone Number LocalPhoneNumber	250-0111
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	RGEN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	6931847028
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55771075
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts, United States
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751323000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	523458000
CY2023Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	0
CY2022Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	100299000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2122000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1365000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	124161000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	116247000
CY2023Q4	us-gaap	Inventory Net InventoryNet	202321000
CY2022Q4	us-gaap	Inventory Net InventoryNet	238277000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33238000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19837000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1111043000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	998118000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	207440000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	190673000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	400486000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	353676000
CY2023Q4	us-gaap	Goodwill Goodwill	987120000
CY2022Q4	us-gaap	Goodwill Goodwill	855513000
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1530000
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	840000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	115515000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	125023000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1277000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	815000
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1713368000
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1526540000
CY2023Q4	us-gaap	Assets Assets	2824411000
CY2022Q4	us-gaap	Assets Assets	2524658000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19563000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	27554000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5631000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6957000
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	12983000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	13950000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	50533000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	71120000
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	69452000
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	284615000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	158162000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	404196000
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	510143000
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0
CY2023Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	40466000
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	23000000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	126578000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	131389000
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	14070000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	51559000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3789000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3814000
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	695046000
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	209762000
CY2023Q4	us-gaap	Liabilities Liabilities	853208000
CY2022Q4	us-gaap	Liabilities Liabilities	613958000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55766078
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55766078
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55557698
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55557698
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	558000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	556000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1569227000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1547266000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-37431000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-34394000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	438849000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	397272000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1971203000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1910700000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2824411000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2524658000
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	638764000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	801536000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	670534000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	353922000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	345830000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	279280000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42722000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43936000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34274000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	218113000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	215829000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	183866000
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-30569000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-28729000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5865000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	584188000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	576866000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	503285000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	54576000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	224670000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	167249000
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	24135000
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	6978000
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	176000
CY2023	us-gaap	Interest Expense InterestExpense	1951000
CY2022	us-gaap	Interest Expense InterestExpense	1162000
CY2021	us-gaap	Interest Expense InterestExpense	11278000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12676000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	rgen	Amortization Of Debt Issuance Cost AmortizationOfDebtIssuanceCost	8075000
CY2022	rgen	Amortization Of Debt Issuance Cost AmortizationOfDebtIssuanceCost	1815000
CY2021	rgen	Amortization Of Debt Issuance Cost AmortizationOfDebtIssuanceCost	1436000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8123000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9531000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1168000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9556000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5530000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13706000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	64132000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	219140000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	153543000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22555000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33181000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25252000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	41577000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	185959000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	128291000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.75
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.35
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.33
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.74
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.24
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.24
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55720
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55460
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55015
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56377
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57455
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57264
CY2023	us-gaap	Net Income Loss NetIncomeLoss	41577000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	185959000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	128291000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3037000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-17508000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-18971000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	38540000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	168451000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	109320000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1529150000
CY2023	rgen	Noncash Interest Income NoncashInterestIncome	2023000
CY2022	rgen	Noncash Interest Income NoncashInterestIncome	0
CY2021	rgen	Noncash Interest Income NoncashInterestIncome	0
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12676000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	128291000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	2000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3879000
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2897000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27500000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-18971000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1750067000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	185959000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	-6000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3707000
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	17018000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27316000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-17508000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1910700000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	41577000
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	-13000
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1076000
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	14386000
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	13227000
CY2023	rgen	Stock Issued During Period Value Contingent Consideration Earnout Payment StockIssuedDuringPeriodValueContingentConsiderationEarnoutPayment	7229000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25575000
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2791000
CY2023	rgen	Deferred Tax Impact On Conversion Feature DeferredTaxImpactOnConversionFeature	-651000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-3037000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1971203000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	41577000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	185959000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	128291000
CY2023	rgen	Amortization Of Inventory Step Up AmortizationOfInventoryStepUp	1238000
CY2022	rgen	Amortization Of Inventory Step Up AmortizationOfInventoryStepUp	0
CY2021	rgen	Amortization Of Inventory Step Up AmortizationOfInventoryStepUp	2130000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	68085000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	50985000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38447000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2448000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1815000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	11530000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	25575000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	27316000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	27500000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2317000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1352000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	6517000
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-30569000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-28729000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5865000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36222000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	84834000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67089000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1231000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	100000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-864000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3312000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3596000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	46523000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-40973000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	57204000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	89781000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13030000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2396000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10192000
CY2023	rgen	Increasedecrease In Operating Lease Right Of Use Asset IncreasedecreaseInOperatingLeaseRightOfUseAsset	-14059000
CY2022	rgen	Increasedecrease In Operating Lease Right Of Use Asset IncreasedecreaseInOperatingLeaseRightOfUseAsset	24549000
CY2021	rgen	Increasedecrease In Operating Lease Right Of Use Asset IncreasedecreaseInOperatingLeaseRightOfUseAsset	4315000
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	461000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	231000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-430000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-9803000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-8197000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	19523000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-27921000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2019000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	23196000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-9229000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	28623000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	6958000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	87000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	966000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1424000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	113918000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	172083000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	119016000
CY2023	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0
CY2022	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	100000000
CY2021	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	102323000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0
CY2023	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	2766000
CY2022	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	3512000
CY2021	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	4187000
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	186642000
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	149893000
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	45000000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-32000
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-110000
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-123275000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-233236000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-221169000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	14386000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	290094000
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1076000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3707000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3879000
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	7253000
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13227000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	17018000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2897000
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	7298000
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-45000
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-26000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-21000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	248961000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13337000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	961000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-11739000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-5866000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-12286000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	227865000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-80356000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-113478000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	523458000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	603814000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	717292000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	751323000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	523458000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	603814000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	26963000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	34365000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	16515000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	988000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1033000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1066000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4335000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	29126000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	85312000
CY2023	us-gaap	Stock Issued1 StockIssued1	13569000
CY2022	us-gaap	Stock Issued1 StockIssued1	0
CY2021	us-gaap	Stock Issued1 StockIssued1	82968000
CY2023	rgen	Fair Value Of Shares Of Common Stock Issued For Contingent Consideration Earnouts FairValueOfSharesOfCommonStockIssuedForContingentConsiderationEarnouts	7229000
CY2022	rgen	Fair Value Of Shares Of Common Stock Issued For Contingent Consideration Earnouts FairValueOfSharesOfCommonStockIssuedForContingentConsiderationEarnouts	0
CY2021	rgen	Fair Value Of Shares Of Common Stock Issued For Contingent Consideration Earnouts FairValueOfSharesOfCommonStockIssuedForContingentConsiderationEarnouts	0
CY2023	rgen	Acquisition Date Fair Value Of Contingent Consideration Earnouts AcquisitionDateFairValueOfContingentConsiderationEarnouts	6640000
CY2022	rgen	Acquisition Date Fair Value Of Contingent Consideration Earnouts AcquisitionDateFairValueOfContingentConsiderationEarnouts	0
CY2021	rgen	Acquisition Date Fair Value Of Contingent Consideration Earnouts AcquisitionDateFairValueOfContingentConsiderationEarnouts	88373000
CY2023	us-gaap	Notes Issued1 NotesIssued1	42179000
CY2022	us-gaap	Notes Issued1 NotesIssued1	0
CY2021	us-gaap	Notes Issued1 NotesIssued1	0
CY2023	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	29634000
CY2022	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0
CY2021	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization and Nature of Business </span></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Repligen Corporation (NASDAQ: RGEN) is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The Company’s franchises include filtration, chromatography, process analytics and proteins. See Part I, Item 1. “</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business - Our Products”, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of this report for additional information related to the Company's products. The Company’s bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. The Company operates under one reportable segment. The Company’s chief operating decision maker (“CODM”), its Chief Executive Officer (“CEO”), reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. See Note 2, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">“Summary of Significant Accounting Policies – Segment Reporting,” </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for more information on the Company’s segment.</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A majority of our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> manufacturing sites are located in the United States (California, Massachusetts, New Hampshire, New Jersey, New York and Texas). Outside the United States, we have manufacturing sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks typically associated with companies in the biotechnology industry. These risks principally include the Company’s dependence on key customers, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with the U.S. Food and Drug Association and other governmental regulations and approval requirements, as well as the ability to grow the Company’s business and obtain adequate funding to finance this growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	rgen	Number Of Manufacturing Sites NumberOfManufacturingSites	19
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant estimates and assumptions by management affect the Company’s revenue recognition for multiple element arrangements, allowance for credit losses, the net realizable value of inventory, valuations and purchase price allocations related to business combinations, contingent consideration, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, estimates related to the fair value of the conversion features of the convertible notes for purposes of assessing whether debt extinguishment or modification accounting applies to the Company’s debt exchange, stock-based compensation, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</span>
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	751300000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	523500000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	603800000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	41577000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	185959000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	128291000
CY2023	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0
CY2022	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	387000
CY2021	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0
CY2023	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	41577000
CY2022	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	186346000
CY2021	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	128291000
CY2023	rgen	Number Of Shares Basic Outstanding NumberOfSharesBasicOutstanding	55720
CY2022	rgen	Number Of Shares Basic Outstanding NumberOfSharesBasicOutstanding	55460
CY2021	rgen	Number Of Shares Basic Outstanding NumberOfSharesBasicOutstanding	55015
CY2023	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	457
CY2022	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	608
CY2021	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	915
CY2023	rgen	Dilutive Securities Effect On Basic Earnings Per Share Convertible Senior Notes DilutiveSecuritiesEffectOnBasicEarningsPerShareConvertibleSeniorNotes	181
CY2022	rgen	Dilutive Securities Effect On Basic Earnings Per Share Convertible Senior Notes DilutiveSecuritiesEffectOnBasicEarningsPerShareConvertibleSeniorNotes	1360
CY2021	rgen	Dilutive Securities Effect On Basic Earnings Per Share Convertible Senior Notes DilutiveSecuritiesEffectOnBasicEarningsPerShareConvertibleSeniorNotes	1253
CY2023	rgen	Dilutive Securities Effect On Basic Earnings Per Share Contingent Consideration DilutiveSecuritiesEffectOnBasicEarningsPerShareContingentConsideration	8
CY2022	rgen	Dilutive Securities Effect On Basic Earnings Per Share Contingent Consideration DilutiveSecuritiesEffectOnBasicEarningsPerShareContingentConsideration	11
CY2021	rgen	Dilutive Securities Effect On Basic Earnings Per Share Contingent Consideration DilutiveSecuritiesEffectOnBasicEarningsPerShareContingentConsideration	0
CY2023	rgen	Weighted Average Number Of Shares Dilutive Effect Of Unvested Performance Stock Units WeightedAverageNumberOfSharesDilutiveEffectOfUnvestedPerformanceStockUnits	11
CY2022	rgen	Weighted Average Number Of Shares Dilutive Effect Of Unvested Performance Stock Units WeightedAverageNumberOfSharesDilutiveEffectOfUnvestedPerformanceStockUnits	16
CY2021	rgen	Weighted Average Number Of Shares Dilutive Effect Of Unvested Performance Stock Units WeightedAverageNumberOfSharesDilutiveEffectOfUnvestedPerformanceStockUnits	81
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	657
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1995
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2249
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56377
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57455
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57264
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.75
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.35
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.33
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.74
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.24
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.24
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	306849
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	177318
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	68968
CY2022	rgen	Dilutive Effect On Shares Of Conversion Premium DilutiveEffectOnSharesOfConversionPremium	1359957
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q4	us-gaap	Assets Assets	2824411000
CY2022Q4	us-gaap	Assets Assets	2524658000
CY2023Q4	rgen	Assets Non Current Excluding Differed Tax Assets AssetsNonCurrentExcludingDifferedTaxAssets	324232000
CY2022Q4	rgen	Assets Non Current Excluding Differed Tax Assets AssetsNonCurrentExcludingDifferedTaxAssets	316511000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Significant Customers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings, limit its credit exposure to any one issuer (with the exception of U.S. treasury obligations) and type of instrument is limited. At December 31, 2023, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> revenue from customers that represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of the Company's total revenue for the year ended December 31, 2023 or 2022. Revenue from Pfizer Inc. accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of total revenue for the year ended December 31, 2021.</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No accounts receivable balance from a specific customer represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of the Company's total trade accounts receivable at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Significant accounts receivable balances representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or more of the Company’s total</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trade </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accounts receivable balances at December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> came from our accounts receivable balance outstanding with Purolite, an Ecolab Inc. company (“Purolite”), which was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company's total trade accounts receivable balance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	rgen	Contingent Consideration Obligation Estimated ContingentConsiderationObligationEstimated	-30600000
CY2022Q4	rgen	Contingent Consideration Obligation Estimated ContingentConsiderationObligationEstimated	-28700000
CY2023	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2023	us-gaap	New Date Of Annual Goodwill Impairment Test NewDateOfAnnualGoodwillImpairmentTest	October 1, 2024
CY2023	us-gaap	Reason For Change In Date Of Annual Goodwill Impairment Test ReasonForChangeInDateOfAnnualGoodwillImpairmentTest	The change is being made to better align the annual impairment assessment date with the Company's annual planning and budgeting process as well as long-term planning and forecasting process.
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2023	us-gaap	Advertising Expense AdvertisingExpense	800000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	600000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	600000
CY2022Q4	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	100000000
CY2022Q4	rgen	Debt Securities Maturity Within One Year Amortized Cost DebtSecuritiesMaturityWithinOneYearAmortizedCost	100299000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	100323000
CY2022Q4	rgen	Debt Securities Maturity Within One Year Amortized Cost DebtSecuritiesMaturityWithinOneYearAmortizedCost	100299000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	100323000
CY2023Q4	rgen	Short Term Contingent Consideration ShortTermContingentConsideration	12983000
CY2023Q4	rgen	Long Term Contingent Consideration LongTermContingentConsideration	14070000
CY2022Q4	rgen	Short Term Contingent Consideration ShortTermContingentConsideration	13950000
CY2022Q4	rgen	Long Term Contingent Consideration LongTermContingentConsideration	51559000
CY2022Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	2700000
CY2021Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	300000
CY2023	us-gaap	Restructuring Costs RestructuringCosts	32200000
CY2023	us-gaap	Restructuring Costs RestructuringCosts	32200000
CY2023	rgen	Noncash Inventory Adjustments NoncashInventoryAdjustments	27600000
CY2023	us-gaap	Restructuring Costs RestructuringCosts	32200000
CY2023	us-gaap	Restructuring Costs RestructuringCosts	32200000
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	4105000
CY2023	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	27631000
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	464000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	115500000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	125000000
CY2023Q4	rgen	Operating Lease Liabilities Excluding Control Not Conveyed Leases OperatingLeaseLiabilitiesExcludingControlNotConveyedLeases	132200000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	138300000
CY2023Q4	us-gaap	Area Of Land AreaOfLand	43833
CY2023	rgen	Increase Decrease In Operating Lease Asset IncreaseDecreaseInOperatingLeaseAsset	4000000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	22585000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	25645000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	25406000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	23944000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	24382000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	79435000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	201397000
CY2023Q4	rgen	Lease Incentives LeaseIncentives	9765000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	32595000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	159037000
CY2023Q4	rgen	Lease Obligations Not Yet Commenced LeaseObligationsNotYetCommenced	26800000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5631000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6957000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	126578000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	131389000
CY2023Q4	rgen	Operating Lease Liabilities Excluding Control Not Conveyed Leases OperatingLeaseLiabilitiesExcludingControlNotConveyedLeases	132209000
CY2022Q4	rgen	Operating Lease Liabilities Excluding Control Not Conveyed Leases OperatingLeaseLiabilitiesExcludingControlNotConveyedLeases	138346000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	20981000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	17833000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	9838000
CY2023	rgen	Variable Operating Lease Cost VariableOperatingLeaseCost	4075000
CY2022	rgen	Variable Operating Lease Cost VariableOperatingLeaseCost	11317000
CY2021	rgen	Variable Operating Lease Cost VariableOperatingLeaseCost	7118000
CY2023	us-gaap	Lease Cost LeaseCost	25056000
CY2022	us-gaap	Lease Cost LeaseCost	29150000
CY2021	us-gaap	Lease Cost LeaseCost	16956000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	17862000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	13757000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	8863000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M26D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0413
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	638764000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	801536000
CY2023Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss ContractWithCustomerReceivableAfterAllowanceForCreditLoss	124161000
CY2022Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss ContractWithCustomerReceivableAfterAllowanceForCreditLoss	116247000
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	10755000
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	19631000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	18751000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	13390000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	124200000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2100000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1365000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1417000
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	82000
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	126000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-839000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-74000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2122000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1365000
CY2021Q4	us-gaap	Goodwill Goodwill	860362000
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	2735000
CY2022Q4	us-gaap	Goodwill Goodwill	855513000
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-1508000
CY2023Q4	us-gaap	Goodwill Goodwill	987120000
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	532454000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	132668000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	399786000
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	533154000
CY2023Q4	rgen	Indefinite Lived Intangible Assets Accumulated Amortization IndefiniteLivedIntangibleAssetsAccumulatedAmortization	-132668000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	400486000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	454130000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	101154000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	352976000
CY2022Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P16Y
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	454830000
CY2022Q4	rgen	Indefinite Lived Intangible Assets Accumulated Amortization IndefiniteLivedIntangibleAssetsAccumulatedAmortization	-101154000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	353676000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	31100000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27100000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22100000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	34314000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	33879000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	33524000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	33421000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	32689000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	231959000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	399786000
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	123598000
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	149438000
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4492000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6183000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	74231000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	82656000
CY2023Q4	us-gaap	Inventory Net InventoryNet	202321000
CY2022Q4	us-gaap	Inventory Net InventoryNet	238277000
CY2023Q4	rgen	Prepaid Services And Professional Fees PrepaidServicesAndProfessionalFees	6605000
CY2022Q4	rgen	Prepaid Services And Professional Fees PrepaidServicesAndProfessionalFees	7135000
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	10229000
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	519000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3087000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1909000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	13317000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	10274000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33238000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19837000
CY2023Q4	us-gaap	Land Land	992000
CY2022Q4	us-gaap	Land Land	1003000
CY2023Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	1667000
CY2022Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	1599000
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	126663000
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	115672000
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	114606000
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	94613000
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	9077000
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	8307000
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	35528000
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	29813000
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	47086000
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	31553000
CY2023Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	544000
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	420000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	336163000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	282980000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	128723000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	92307000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	207440000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	190673000
CY2023	us-gaap	Depreciation Depreciation	37000000
CY2022	us-gaap	Depreciation Depreciation	23900000
CY2021	us-gaap	Depreciation Depreciation	16400000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16660000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	33522000
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	10287000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	19283000
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	6814000
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2459000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	16772000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15856000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	50533000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	71120000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-17601000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	153446000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	81984000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	81733000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	65694000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	71559000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	64132000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	219140000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	153543000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	20238000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	34800000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	20166000
CY2023	rgen	Provision For Deferred Income Tax Expense Benefit ProvisionForDeferredIncomeTaxExpenseBenefit	2317000
CY2022	rgen	Provision For Deferred Income Tax Expense Benefit ProvisionForDeferredIncomeTaxExpenseBenefit	-1619000
CY2021	rgen	Provision For Deferred Income Tax Expense Benefit ProvisionForDeferredIncomeTaxExpenseBenefit	5086000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22555000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33181000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25252000
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	3512000
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	17662000
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	8321000
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	142000
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	1381000
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	1251000
CY2023	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	18901000
CY2022	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	14138000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	13469000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	46020000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	32247000
CY2021	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	15680000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22555000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33181000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25252000
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4900000
CY2023	us-gaap	Other Information Pertaining To Income Taxes OtherInformationPertainingToIncomeTaxes	at various dates through 2043
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5120000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5323000
CY2023Q4	rgen	Deferred Tax Assets Operating Leases DeferredTaxAssetsOperatingLeases	30727000
CY2022Q4	rgen	Deferred Tax Assets Operating Leases DeferredTaxAssetsOperatingLeases	31564000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	17568000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9102000
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	10131000
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	5983000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7578000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9808000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4697000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2639000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	5314000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	4440000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	81135000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	68859000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	81115000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	68840000
CY2023Q4	rgen	Deferred Income Tax Liabilities Fixed Assets DeferredIncomeTaxLiabilitiesFixedAssets	-17716000
CY2022Q4	rgen	Deferred Income Tax Liabilities Fixed Assets DeferredIncomeTaxLiabilitiesFixedAssets	-18965000
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	56956000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	43549000
CY2023Q4	rgen	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	-26373000
CY2022Q4	rgen	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	-28486000
CY2023Q4	rgen	Deferred Tax Liabilities Debt Discount DeferredTaxLiabilitiesDebtDiscount	19006000
CY2022Q4	rgen	Deferred Tax Liabilities Debt Discount DeferredTaxLiabilitiesDebtDiscount	0
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	120051000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	91000000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	38936000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	22160000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1000000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	700000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	64132000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	219140000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	153543000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1084000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.017
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1024000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.005
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	530000
CY2023	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	4522000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.071
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1387000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.022
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	3509000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.016
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1462000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	5139000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.023
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	2239000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.015
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2461000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.038
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-5638000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.026
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-9049000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.059
CY2023	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	343000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0.005
CY2022	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	83000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0
CY2021	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	30000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	88000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	5042000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0.023
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	2547000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0.017
CY2023	rgen	Income Tax Reconciliation Nondeductible Expense Executive Compensation IncomeTaxReconciliationNondeductibleExpenseExecutiveCompensation	3084000
CY2023	rgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensation	0.048
CY2022	rgen	Income Tax Reconciliation Nondeductible Expense Executive Compensation IncomeTaxReconciliationNondeductibleExpenseExecutiveCompensation	5441000
CY2022	rgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensation	0.025
CY2021	rgen	Income Tax Reconciliation Nondeductible Expense Executive Compensation IncomeTaxReconciliationNondeductibleExpenseExecutiveCompensation	3397000
CY2021	rgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensation	0.022
CY2023	rgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Contingent Consideration Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseContingentConsiderationAmount	-6412000
CY2023	rgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseContingentConsiderationPercent	-0.10
CY2022	rgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Contingent Consideration Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseContingentConsiderationAmount	-6033000
CY2022	rgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseContingentConsiderationPercent	-0.028
CY2021	rgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Contingent Consideration Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseContingentConsiderationAmount	1232000
CY2021	rgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseContingentConsiderationPercent	0.008
CY2023	rgen	Effective Income Tax Rate Reconciliation Loss On Debt Exchange EffectiveIncomeTaxRateReconciliationLossOnDebtExchange	2634000
CY2023	rgen	Effective Income Tax Rate Reconciliation Loss On Debt Exchange Percent EffectiveIncomeTaxRateReconciliationLossOnDebtExchangePercent	0.041
CY2022	rgen	Effective Income Tax Rate Reconciliation Loss On Debt Exchange EffectiveIncomeTaxRateReconciliationLossOnDebtExchange	0
CY2022	rgen	Effective Income Tax Rate Reconciliation Loss On Debt Exchange Percent EffectiveIncomeTaxRateReconciliationLossOnDebtExchangePercent	0
CY2021	rgen	Effective Income Tax Rate Reconciliation Loss On Debt Exchange EffectiveIncomeTaxRateReconciliationLossOnDebtExchange	0
CY2021	rgen	Effective Income Tax Rate Reconciliation Loss On Debt Exchange Percent EffectiveIncomeTaxRateReconciliationLossOnDebtExchangePercent	0
CY2023	rgen	Effective Income Tax Rate Reconciliation Debt Discount EffectiveIncomeTaxRateReconciliationDebtDiscount	16650000
CY2023	rgen	Effective Income Tax Rate Reconciliation Debt Discount Percentage EffectiveIncomeTaxRateReconciliationDebtDiscountPercentage	0.26
CY2022	rgen	Effective Income Tax Rate Reconciliation Debt Discount EffectiveIncomeTaxRateReconciliationDebtDiscount	0
CY2022	rgen	Effective Income Tax Rate Reconciliation Debt Discount Percentage EffectiveIncomeTaxRateReconciliationDebtDiscountPercentage	0
CY2021	rgen	Effective Income Tax Rate Reconciliation Debt Discount EffectiveIncomeTaxRateReconciliationDebtDiscount	0
CY2021	rgen	Effective Income Tax Rate Reconciliation Debt Discount Percentage EffectiveIncomeTaxRateReconciliationDebtDiscountPercentage	0
CY2023	rgen	Effective Income Tax Rate Reconciliation Foreign Exchange Loss EffectiveIncomeTaxRateReconciliationForeignExchangeLoss	-2288000
CY2023	rgen	Effective Income Tax Rate Reconciliation Foreign Exchange Loss Percent EffectiveIncomeTaxRateReconciliationForeignExchangeLossPercent	-0.036
CY2022	rgen	Effective Income Tax Rate Reconciliation Foreign Exchange Loss EffectiveIncomeTaxRateReconciliationForeignExchangeLoss	0
CY2022	rgen	Effective Income Tax Rate Reconciliation Foreign Exchange Loss Percent EffectiveIncomeTaxRateReconciliationForeignExchangeLossPercent	0
CY2021	rgen	Effective Income Tax Rate Reconciliation Foreign Exchange Loss EffectiveIncomeTaxRateReconciliationForeignExchangeLoss	0
CY2021	rgen	Effective Income Tax Rate Reconciliation Foreign Exchange Loss Percent EffectiveIncomeTaxRateReconciliationForeignExchangeLossPercent	0
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	165000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.003
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	234000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.001
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-443000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.003
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-688000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.003
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-48000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0
CY2023	rgen	Income Tax Reconciliation Return To Provision Adjustments IncomeTaxReconciliationReturnToProvisionAdjustments	-1255000
CY2023	rgen	Effective Income Tax Rate Reconciliation Return To Provision Adjustments EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments	-0.02
CY2022	rgen	Income Tax Reconciliation Return To Provision Adjustments IncomeTaxReconciliationReturnToProvisionAdjustments	-498000
CY2022	rgen	Effective Income Tax Rate Reconciliation Return To Provision Adjustments EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments	-0.002
CY2021	rgen	Income Tax Reconciliation Return To Provision Adjustments IncomeTaxReconciliationReturnToProvisionAdjustments	-50000
CY2021	rgen	Effective Income Tax Rate Reconciliation Return To Provision Adjustments EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments	0
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	765000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.012
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-92000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	730000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.005
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22555000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.352
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33181000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.151
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25252000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.164
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2996000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2786000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	178000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	146000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	53000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	64000
CY2023	rgen	Unrecognized Tax Benefits Period Gross Decreases Release UnrecognizedTaxBenefitsPeriodGrossDecreasesRelease	88000
CY2022	rgen	Unrecognized Tax Benefits Period Gross Decreases Release UnrecognizedTaxBenefitsPeriodGrossDecreasesRelease	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3139000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2996000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3100000
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	15000000
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	24000000
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	67000000
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	52000000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	1100000
CY2023Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	212400000
CY2023	rgen	Foreign Earnings Subject To One Time Transition Tax ForeignEarningsSubjectToOneTimeTransitionTax	5700000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	25600000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	27300000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	27500000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	25575000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	27316000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	27500000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.4478
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.4658
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.4144
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.4396
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.4457
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.4527
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0356
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0471
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0186
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0407
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0077
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0107
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	609965
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	71.74
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	90305
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	168.22
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	40211
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	26.76
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	10929
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	189.46
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	649130
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	85.97
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	364443
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	65.53
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	635834
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	85.49
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y7M2D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	61888000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5800000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14100000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	20300000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	84.37
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	87.40
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	88.01
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4700000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3100000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3000000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	531034
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	142.57
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	212338
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	170.03
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	195672
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	124.58
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	73380
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	177.81
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	474320
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	155.59
CY2023	rgen	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber	413249
CY2023Q4	rgen	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue	152.74
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	63800000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M2D
CY2023Q4	rgen	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Equity Instruments Other Than Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedNumberOfShares	2185873
CY2023Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	34300000
CY2023	rgen	Debt Instrument Convertible Into Equity Settled DebtInstrumentConvertibleIntoEquitySettled	100000
CY2023	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	0.25

Files In Submission

Name	View Source	Status
0000950170-24-018809-index-headers.html	Edgar Link	pending
0000950170-24-018809-index.html	Edgar Link	pending
0000950170-24-018809.txt	Edgar Link	pending
0000950170-24-018809-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img33618189_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgen-20231231.htm	Edgar Link	pending
rgen-20231231.xsd	Edgar Link	pending
rgen-ex10_5.htm	Edgar Link	pending
rgen-ex19_1.htm	Edgar Link	pending
rgen-ex21_1.htm	Edgar Link	pending
rgen-ex23_1.htm	Edgar Link	pending
rgen-ex31_1.htm	Edgar Link	pending
rgen-ex31_2.htm	Edgar Link	pending
rgen-ex32_1.htm	Edgar Link	pending
rgen-ex97_1.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rgen-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGEN
REPLIGEN CORP Stock $rgen

2024 Q1 Form 10-K Financial Statement

#000095017024018809 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGEN REPLIGEN CORP Stock $rgen

2024 Q1 Form 10-K Financial Statement

#000095017024018809 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGEN
REPLIGEN CORP Stock $rgen